Curriculum Group Wraps up Inaugural Fellows’ Training Series
Our national neuromuscular lecture series launched last August 2022 has just wrapped up! The series consisted of a weekly (38 weeks) virtual Royal College CPD-accredited curriculum for neuromuscular fellows presented by subject-matter experts, developed by the curriculum working group together with the directors of fellowship programs across Canada.
In total, 33 neuromuscular fellows participated in the inaugural lecture series, from adult and pediatric neuromuscular and physiatry fellowship programs from across Canada. The pilot lecture series received extremely positive feedback, with fellows sharing that the series was informative, applicable to their practice, and indicated a high degree of satisfaction overall.
Building on this successful collaboration between Canadian fellowship programs, the planning committee is currently preparing the second iteration of the program, set to begin in mid-August 2023 for a new cohort of Canadian neuromuscular fellows.
For more information, please contact network administrative coordinator James Davis at .
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.